A field survey was done in Ezbet El-Bakly, Al-Fayoum Governorate, Egypt to assess the efficacy and safety of
Mirazid in the treatment of human
fascioliasis. Among 1019 individuals examined for parasitosis, the prevalence of
fascioliasis was 1.7% and the geometric mean egg count (GMEC) was 33.2 eggs/gram stools. About 23.5% of the
fascioliasis patients were asymptomatic. The most frequent symptoms were abdominal dis\tension and
flatulence (76.5%), right hypochondrial
pain (17.6%) and epigastric
pain (17.6%). The most prevalent signs were pallor (52.9%,), tender right hypochondrium (23.5%) and tinge of
jaundice (17.6%). All cases were treated by
Mirazid as two capsules (600 mg) on an empty stomach an hour before breakfast for six consecutive days and followed up clinically and parasitologically. The parasitological cure rate, two and three months
after treatment was 88.2% and 94.1% with an overt clinical cure without any side-effects. The cases not completely responding to a single course of treatment showed a marked reduction of the egg intensity. It was concluded that
Mirazid (or
Myrrh extract of Commiphora molmol) is safe and effective in the treatment of human
fascioliasis under the field conditions.